Compare

Centene vs Elevance Health

MonkScore ranges and fundamentals, side by side

Key facts

Centene and Elevance Health: key facts

  • In fiscal 2025, Centene Corp. reported revenue of $194.8B and net income of -$6.7B.
  • In fiscal 2025, Elevance Health Inc. reported revenue of $199.1B and net income of $5.7B.
  • Centene Corp.'s revenue grew 11.5% a year from fiscal 2021 to fiscal 2025.
  • Elevance Health Inc.'s revenue grew 9.5% a year from fiscal 2021 to fiscal 2025.
  • Centene Corp.'s free cash flow was positive in 4 of the 5 fiscal years from 2021 to 2025.
  • Elevance Health Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 September 2026, Centene Corp. reported revenue of $194.7B and net income of $1.5B.
  • In the twelve months to 30 September 2026, Elevance Health Inc. reported revenue of $201.8B and net income of $5.1B.

Side by side

Centene and Elevance Health, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureCentene Corp.NYSE:CNCElevance Health Inc.NYSE:ELV
MonkScore
MonkScore range40–50as of October 202630–40as of October 2026
Sector rank414 of 628 in Healthcare422 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryMedical - Healthcare PlansMedical - Healthcare Plans
Latest fiscal year
Revenue$194.8BFY 2025$199.1BFY 2025
Net income-$6.7BFY 2025$5.7BFY 2025
Free cash flow$4.3BFY 2025$3.2BFY 2025
Operating cash flow$5.1BFY 2025$4.3BFY 2025
Total debt$18.8BFY 2025$33.2BFY 2025
Cash$17.9BFY 2025$9.5BFY 2025
Last 12 months
Revenue$194.7Bto 30 September 2026$201.8Bto 30 September 2026
Net income$1.5Bto 30 September 2026$5.1Bto 30 September 2026
Free cash flow$4.0Bto 30 September 2026$6.5Bto 30 September 2026
Operating cash flow$4.7Bto 30 September 2026$7.6Bto 30 September 2026
Total debt$15.5Bto 30 September 2026$30.8Bto 30 September 2026
Cash$20.7Bto 30 September 2026$10.3Bto 30 September 2026

MonkStreet provides research, not investment advice.